.Pharmacolibrary.Drugs.C_CardiovascularSystem.C02K_OtherAntihypertensives.C02KX52_AmbrisentanAndTadalafil.AmbrisentanAndTadalafil .Pharmacolibrary.Drugs.C_CardiovascularSystem.C02K_OtherAntihypertensives.C02KX52_AmbrisentanAndTadalafil.AmbrisentanAndTadalafil| name: | AmbrisentanAndTadalafil |
| ATC code: | C02KX52 | route: | oral |
| n-compartments | 2 |
Ambrisentan and tadalafil is a fixed-dose combination medication approved for the treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity. Ambrisentan is an endothelin receptor antagonist and tadalafil is a phosphodiesterase type 5 inhibitor. The combination is used to target different pathways involved in PAH and is currently approved for use in several regions.
Estimated pharmacokinetic parameters for healthy adults using literature values for individual ambrisentan and tadalafil; no dedicated published population PK model for the fixed-dose combination available.
Yokoyama, Y, et al., & Itoh, K (2014). Simultaneous microdetermination of bosentan, ambrisentan, sildenafil, and tadalafil in plasma using liquid chromatography/tandem mass spectrometry for pediatric patients with pulmonary arterial hypertension. Journal of pharmaceutical and biomedical analysis 89 227–232. DOI:10.1016/j.jpba.2013.11.007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24309556